Several drugmakers are expected to announce agreements with the U.S. government to lower prescription drug prices, Michael Erman, Jarrett Renshaw and Patrick Wingrove of Reuters reports, citing people familiar with the matter. AbbVie (ABBV), Bristol Myers Squibb (BMY), Gilead (GILD), Merck (MRK), Novartis (NVS), and Roche (RHHBY) are among the companies expected to announce deals.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- AbbVie Stock Slips on U.S. Government Price Negotiations Reports
- AbbVie price target lowered to $233 from $248 at BofA
- AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges
- AbbVie’s New Study on Parkinson’s Treatment: What Investors Need to Know